Key Takeaways
- • Hedge-fund managers with high testosterone underperform those with low testosterone by 5.8 percent annually, according to a joint study by University of Central Florida and Singapore Management University analyzing over 3,000 managers.
- • Researchers used facial width-to-height ratio (fWHR) as a proxy for testosterone levels and found that high-testosterone managers face greater termination risk despite controlling for market conditions and risk variables.
- • High-testosterone managers exhibit behavioral patterns that damage returns: excessive trading frequency, preference for lottery-like stocks, and susceptibility to the disposition effect (holding losers while selling winners).
- • Fund-of-funds managers exhibit homophilic selection bias, with higher-testosterone investors preferentially allocating capital to higher-testosterone hedge-fund managers, creating systematic capital misallocation.
- • The hedge-fund industry's structural underperformance—returning just 0.14 percent year-to-date while lagging the S&P 500—may be partially attributable to the industry's cultural emphasis on aggression and competitiveness that attracts and elevates high-testosterone leadership.
Summary
A peer-reviewed study conducted jointly by the University of Central Florida and Singapore Management University has identified a quantifiable performance penalty associated with elevated testosterone levels in hedge-fund management. Using facial width-to-height ratio (fWHR)—an established biometric proxy for testosterone concentration—researchers analyzed the fund portfolios and career outcomes of more than 3,000 hedge-fund managers. The results reveal a stark performance differential: funds operated by high-testosterone managers systematically underperform their low-testosterone counterparts by 5.8 percent annually on a risk-adjusted basis.
The research controlled for conventional performance variables including market environment and fund-level risk exposure, strengthening the causal inference. Beyond pure return metrics, high-testosterone managers demonstrated elevated termination rates, suggesting that institutional investors and allocators ultimately penalize this behavioral profile through capital withdrawal and manager replacement. The study attributes underperformance to three primary behavioral pathologies: excessive portfolio turnover, pronounced preference for high-volatility "lottery-like" equities, and manifestation of the disposition effect—the well-documented cognitive bias wherein investors prematurely realize gains while irrationally retaining underwater positions.
A particularly significant finding involves the selection behavior of fund-of-funds allocators. Rather than acting as contrarian filters, fund-of-funds managers exhibit homophilic capital allocation patterns: high-testosterone fund-of-funds systematically overweight allocations to high-testosterone hedge-fund managers, while low-testosterone allocators preferentially select lower-testosterone managers. This self-sorting mechanism amplifies rather than corrects the performance drag associated with elevated testosterone exposure.
The research carries implications for hedge-fund industry structure and culture. The sector has historically valorized aggression, competitive intensity, and dominance-seeking behavior as markers of investment acumen—traits neurologically and behaviorally correlated with elevated testosterone. The 0.14 percent aggregate year-to-date return reported by Hedge Fund Research, coupled with persistent underperformance relative to the S&P 500 during both bull and volatile market regimes, suggests that the industry's cultural selection for testosterone-driven leadership may represent a structural drag on collective performance. The study implies that hedge-fund performance optimization may require cultural recalibration toward discipline, loss-aversion management, and reduced portfolio churn—behavioral traits associated with lower testosterone profiles.
The research controlled for conventional performance variables including market environment and fund-level risk exposure, strengthening the causal inference. Beyond pure return metrics, high-testosterone managers demonstrated elevated termination rates, suggesting that institutional investors and allocators ultimately penalize this behavioral profile through capital withdrawal and manager replacement. The study attributes underperformance to three primary behavioral pathologies: excessive portfolio turnover, pronounced preference for high-volatility "lottery-like" equities, and manifestation of the disposition effect—the well-documented cognitive bias wherein investors prematurely realize gains while irrationally retaining underwater positions.
A particularly significant finding involves the selection behavior of fund-of-funds allocators. Rather than acting as contrarian filters, fund-of-funds managers exhibit homophilic capital allocation patterns: high-testosterone fund-of-funds systematically overweight allocations to high-testosterone hedge-fund managers, while low-testosterone allocators preferentially select lower-testosterone managers. This self-sorting mechanism amplifies rather than corrects the performance drag associated with elevated testosterone exposure.
The research carries implications for hedge-fund industry structure and culture. The sector has historically valorized aggression, competitive intensity, and dominance-seeking behavior as markers of investment acumen—traits neurologically and behaviorally correlated with elevated testosterone. The 0.14 percent aggregate year-to-date return reported by Hedge Fund Research, coupled with persistent underperformance relative to the S&P 500 during both bull and volatile market regimes, suggests that the industry's cultural selection for testosterone-driven leadership may represent a structural drag on collective performance. The study implies that hedge-fund performance optimization may require cultural recalibration toward discipline, loss-aversion management, and reduced portfolio churn—behavioral traits associated with lower testosterone profiles.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.